Sanofi Has EU Insulin Aspart Biosimilar Approval

Firm Comments on Pricing And Launch Plans For Rival To NovoRapid

Sanofi has received formal approval from the European Commission for its insulin aspart biosimilar.

Thumbs_Up_EU
The European Commission has formally approved Sanofi’s insulin aspart biosimilar • Source: Shutterstock

Sanofi has received formal European Commission approval granting a pan-European marketing authorization for its insulin aspart biosimilar.

The approval comes after the firm garnered a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Biosimilars

More from Products

  • For Generics, A Victory Lap – And A Warning – On Drug Shortages

    Avoiding disaster at the beginning of the pandemic and offering a pro-active supply chain blueprint should position the generics industry well for an onshoring debate in Congress, but a look back at March 2020 is a reminder that even small policy shifts can have a big impact.

  • GB-Free-Company-The Secret to Walking More: It’s Not Counting Steps

    We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.

  • Biocon And Teva Sign Up To Biosimilars Forum

    Teva and Biocon Biologics have become the latest firms to sign up to the Biosimilars Forum industry association in the US.